Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2416128rdf:typepubmed:Citationlld:pubmed
pubmed-article:2416128lifeskim:mentionsumls-concept:C0021051lld:lifeskim
pubmed-article:2416128lifeskim:mentionsumls-concept:C0305052lld:lifeskim
pubmed-article:2416128lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:2416128pubmed:dateCreated1985-12-24lld:pubmed
pubmed-article:2416128pubmed:abstractTextThis study was undertaken to compare intravenous gamma-globulin (IVGG) for 1 year in patients with primary immune defects who had previously been treated with intramuscular gamma-globulin (IMGG). Forty-three patients were available for analysis. After administration of 300 mg/kg of IVGG every 3 weeks, blood immunoglobulin levels increased to within 1 SD of normal for the patient's ages. In 5 patients, this dosage regimen did not raise the immunoglobulin levels satisfactorily, although they were still better than those achieved with IMGG. In 18 patients, treatment benefits became apparent after 5 - 6 months of treatment. Substantial improvement was observed in 70% of these patients. Sixteen reactions occurred with 638 infusions, an incidence rate of 2.5%. If 2 patients with an IgM macroglobulin and 1 patient with an anti-IgA antibody were excluded, the reaction incidence would probably have been 1%.lld:pubmed
pubmed-article:2416128pubmed:languageenglld:pubmed
pubmed-article:2416128pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2416128pubmed:citationSubsetIMlld:pubmed
pubmed-article:2416128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2416128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2416128pubmed:statusMEDLINElld:pubmed
pubmed-article:2416128pubmed:issn0042-9007lld:pubmed
pubmed-article:2416128pubmed:authorpubmed-author:Cunningham-Ru...lld:pubmed
pubmed-article:2416128pubmed:issnTypePrintlld:pubmed
pubmed-article:2416128pubmed:volume49 Suppl 1lld:pubmed
pubmed-article:2416128pubmed:ownerNLMlld:pubmed
pubmed-article:2416128pubmed:authorsCompleteYlld:pubmed
pubmed-article:2416128pubmed:pagination8-14lld:pubmed
pubmed-article:2416128pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:2416128pubmed:meshHeadingpubmed-meshheading:2416128-...lld:pubmed
pubmed-article:2416128pubmed:meshHeadingpubmed-meshheading:2416128-...lld:pubmed
pubmed-article:2416128pubmed:meshHeadingpubmed-meshheading:2416128-...lld:pubmed
pubmed-article:2416128pubmed:meshHeadingpubmed-meshheading:2416128-...lld:pubmed
pubmed-article:2416128pubmed:meshHeadingpubmed-meshheading:2416128-...lld:pubmed
pubmed-article:2416128pubmed:meshHeadingpubmed-meshheading:2416128-...lld:pubmed
pubmed-article:2416128pubmed:meshHeadingpubmed-meshheading:2416128-...lld:pubmed
pubmed-article:2416128pubmed:year1985lld:pubmed
pubmed-article:2416128pubmed:articleTitleIntravenous immune serum globulin in immunodeficiency.lld:pubmed
pubmed-article:2416128pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2416128lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2416128lld:pubmed